SMN1 and proximal spinal muscular atrophy: (ii) Zolgensma (onasemnogene abeparvovec), developed by Novartis and approved in 2019 for the treatment of spinal muscular atrophy (SMA) in pediatric patients under 2 years of age, using AAV9 vector to deliver functional SMN1 gene to motor neurons [138,272].